Nucleoproteins, E.g., Chromatin, Chromosomal Proteins, Histones, Protamines, Salmine, Etc. Patents (Class 530/358)
  • Patent number: 9686993
    Abstract: The present invention provides a method for prominently inhibiting the production in fungi of mycotoxin, which has serious effects on health of humans and other animals, and provides a mycotoxin production inhibitor. Mycotoxin content such as deoxinivalenol (DON) in harvested crops can be reduced without a correlation with the control effects against fungi by spraying a fungicide containing a benzimidazole-type fungicidal compound such as thiophanate-methyl as an active ingredient onto food crops such as wheat, barley, and the like. Concomitant use of the benzimidazole-type fungicidal compound and a sterol biosynthesis inhibitor (SBI agent) such as tebuconazole can further enhance the effect.
    Type: Grant
    Filed: March 29, 2006
    Date of Patent: June 27, 2017
    Assignee: Nippon Soda Co., Ltd.
    Inventor: Herbert Buschhaus
  • Patent number: 9522941
    Abstract: Chromatin-associated proteins and other factors and their related methods and compositions are isolated and identified.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: December 20, 2016
    Assignee: Case Western Reserve University
    Inventor: Erik D. Andrulis
  • Patent number: 9023957
    Abstract: The present invention generally relates to processes and methods of peptide and protein synthesis. The present invention also relates to specific compounds for use in such processes and methods. It is shown herein that peptides with a C-terminal tertiary N,N-bis(2-mercaptoethyl)-amide (BMEA) undergo N-to-S acyl transfer at weakly acidic pH to form a transient thioester which can be captured for direct ligation with a cysteinyl peptide. These C-terminal BMEA peptides are easily prepared with standard Fmoc solid-phase synthesis protocols, thus giving a very convenient access to the thioester components for native chemical ligation.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: May 5, 2015
    Assignee: Nanyang Technological University
    Inventor: Chuan Fa Liu
  • Publication number: 20150105326
    Abstract: The present invention provides an isolated methyl degron peptide and a fusion protein comprising a methyl degron peptide. Also, the present invention provides screening methods for agents affecting protein lifespan and anti-cancer agents. Moreover, the present invention provides methods of controlling protein lifespan, regulating protein expression, and treating cancers by using a methyl degron peptide or a methyl degron gene.
    Type: Application
    Filed: October 11, 2013
    Publication date: April 16, 2015
    Applicant: Seoul National University (SNU) R&D Foundation
    Inventor: Sung Hee BAEK
  • Publication number: 20150099269
    Abstract: The present invention discloses a transcription activator-like effector-based strategy, termed “TALEColor”, for labeling specific repetitive DNA sequences in human chromosomes. TALEs were custom designed for human telomeric repeats and fused with any of numerous fluorescent proteins (FPs). TALE-telomere-FP fusion proteins were used to detect telomeric sequence in both living cells and fixed cells. Using human cells with different average telomere lengths, TALEColor signals correlated positively with telomere length. TALEs were also designed to detect centromeric sequences unique to specific chromosomes, enabling localization of these specific human chromosomes in live cells. These methods may have significant potential both for basic chromosome and genome research as well as in clinical applications.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventor: Hanhui Ma
  • Patent number: 8999380
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Grant
    Filed: March 9, 2013
    Date of Patent: April 7, 2015
    Assignee: Moderna Therapeutics, Inc.
    Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Sayda M. Elbashir, Matthias John, Atanu Roy, Susan Whoriskey, Kristy M. Wood, Paul Hatala, Jason P. Schrum, Kenechi Ejebe, Jeff Lynn Ellsworth, Justin Guild
  • Publication number: 20150096064
    Abstract: The present invention relates to sequence and structural features of single-stranded (ss)RNA molecules required to mediate target-specific nucleic acid modifications by RNA-interference (RNAi), such as target mRNA degradation and/or DNA methylation.
    Type: Application
    Filed: July 22, 2014
    Publication date: April 2, 2015
    Applicant: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Thomas TUSCHL, Javier MARTINEZ, Agnieszka PATKANIOWSKA, Henning URLAUB, Reinhard LUEHRMANN
  • Publication number: 20150087601
    Abstract: It is an object of the present invention to provide: a polyion complex that sufficiently retains a photosensitizing substance in serum and is excellent in terms of structural stability; a nucleic acid polyplex as a constituent thereof; and a device and a kit for delivering a nucleic acid into a cell. The nucleic acid polyplex of the present invention comprises a cationic polymer represented by general formula (1) and a nucleic acid. The polyion complex of the present invention comprises the nucleic acid polyplex of the present invention and an anionic photosensitizing substance.
    Type: Application
    Filed: November 3, 2014
    Publication date: March 26, 2015
    Inventors: Kazunori KATAOKA, Yuichi YAMASAKI, Nobuhiro NISHIYAMA, Woo-Dong JANG, Anwar ARNIDA
  • Publication number: 20150079629
    Abstract: The invention relates to a nucleic acid which is stabilised against decomposition by exonucleases. Said nucleic acid contains the following constituents: a) a code sequence coding for a defined protein, b) optionally, a promoter sequence controlling the expression of the code sequence, and c) at least one molecule A added to an end of the linear sequence containing the constituents a and b, said molecule being linked to a non-immobilised, volumic molecule B.
    Type: Application
    Filed: November 24, 2014
    Publication date: March 19, 2015
    Inventors: Helmut Merk, Wolfgang Stiege
  • Publication number: 20150068904
    Abstract: The invention relates to mutant forms of lysenin. The invention also relates to analyte characterisation using lysenin.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 12, 2015
    Applicant: OXFORD NANOPORE TECHNOLOGIES LIMITED
    Inventors: Mark Bruce, James Clarke, Andrew Heron, Lakmal Jayasinghe, Jayne Wallace
  • Publication number: 20150071986
    Abstract: The present invention concerns a pharmaceutical composition comprising virtosomes isolated from non-dividing cells or the medium in which the cells are grown, for use in the inhibition of tumour growth and/or prevention of metastases.
    Type: Application
    Filed: May 29, 2014
    Publication date: March 12, 2015
    Applicant: The Foundation for Biomedical Research of La Paz University Hospital (FIBHULP)
    Inventors: Damián GARCIA-OLMO, Mariano Garcia-Arranz, Luz Vega Clemente, Peter Brian Gahan, Maurice Stroun
  • Publication number: 20150024458
    Abstract: Disclosed herein are methods and compositions dock and lock (DNL) complexes comprising an AD moiety selected from an AKAP protein and a DDD moiety selected from a protein kinase A regulatory subunit. Also disclosed are fusion proteins comprising an AD moiety or DDD moiety attached to an effector moiety. The DDD moieties form dimers that bind to the AD moiety to form the DNL complexes. The effector moieties may be selected from a wide range of known effector moieties that produce one or more physiological effects, including but not limited to cell death. The DNL complexes may further comprise one or more diagnostic and/or therapeutic agents. The DNL complexes are of use for treating and/or diagnosing a variety of diseases or conditions.
    Type: Application
    Filed: October 1, 2014
    Publication date: January 22, 2015
    Inventors: Chien-Hsing Chang, David M. Goldenberg
  • Publication number: 20150018523
    Abstract: This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, orthogonal pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells are also provided.
    Type: Application
    Filed: July 22, 2014
    Publication date: January 15, 2015
    Inventors: Alexander Deiters, T. Ashton Cropp, Jason W. Chin, J. Christopher Anderson, Peter G. Schultz
  • Publication number: 20150018236
    Abstract: Methods for screening libraries of polypeptides for biologically activity on cells. For example, polypeptides can be synthesized and encapsulated along with their coding sequences in microcapsules of an emulsion. Emulsion microcapsules can then be fused with microcapsules comprising test cells and biological activity on the cells is assessed to identify biologically active polypeptides and nucleic acid molecules encoding the same.
    Type: Application
    Filed: February 1, 2013
    Publication date: January 15, 2015
    Applicant: Invenra Inc.
    Inventors: Roland Green, Bryan Glaser, Ivar Meyvantsson, Kimberly Kaufman, Madison Green
  • Publication number: 20150017444
    Abstract: A method for lattice design via multivalent linkers (LDML) is disclosed that introduces a rationally designed symmetry of connections between particles in order to achieve control over the morphology of their assembly. The method affords the inclusion of different programmable interactions within one linker that allow an assembly of different types of particles. The designed symmetry of connections is preferably provided utilizing DNA encoding. The linkers may include fabricated “patchy” particles, DNA scaffold constructs and Y-shaped DNA linkers, anisotropic particles, which are preferably functionalized with DNA, multimeric protein-DNA complexes, and particles with finite numbers of DNA linkers.
    Type: Application
    Filed: January 18, 2013
    Publication date: January 15, 2015
    Inventors: Oleg Gang, Fang Lu, Miho Tagawa
  • Publication number: 20150010494
    Abstract: A method of preparing an oxidised polysaccharide-protein conjugate by oxidising a polysaccharide with an oxidising agent to form an oxidised polysaccharide and combining such oxidised polysaccharide with a protein. The oxidised polysaccharide is reacted with a protein to form a composition comprising a conjugate wherein the oxidised polysaccharide and the protein are conjugated via one or more imine bonds and wherein the oxidised polysaccharide comprises essentially no alpha-hydroxy aldehyde units. The conjugate may be used to provide sustained or latent activity of the protein.
    Type: Application
    Filed: September 22, 2014
    Publication date: January 8, 2015
    Inventors: Gord Adamson, David Bell, Steven Brookes
  • Publication number: 20140377295
    Abstract: This disclosure provides universal influenza vaccines which can provide extended protection for several years, provide improved protection to circulating influenza strains that were not predicted accurately for annual vaccine manufacturing, and provide protection against newly emerging strains of influenza virus which carry the potential for establishing global pandemics.
    Type: Application
    Filed: May 23, 2012
    Publication date: December 25, 2014
    Applicant: THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
    Inventors: Hildegund C. Ertl, Dongming Zhou
  • Publication number: 20140377179
    Abstract: The present invention features compositions and methods that make use of complexes comprising one or more inhibitory nucleic acids and a targeting polypeptide, wherein the targeting polypeptide consists of a cell surface receptor ligand. The compositions can be used in methods of silencing gene expression in a cell, in delivering agents to a target cell, and in treating or preventing a disease or disorder in a subject.
    Type: Application
    Filed: March 20, 2014
    Publication date: December 25, 2014
    Applicant: The United States of America,as represented by the Secretary, Department of Health & Human Services
    Inventors: Bira Arya, Purevdorj Olkhanud, Juan Espinoza
  • Publication number: 20140377868
    Abstract: Methods and constructs for RNA-guided targeting of transcriptional activators to specific genomic loci.
    Type: Application
    Filed: March 14, 2014
    Publication date: December 25, 2014
    Inventors: J. Keith Joung, Morgan Maeder
  • Patent number: 8895701
    Abstract: Conjugates for the efficient delivery of sequence-specific antisense to cells of a selected type for the inhibition of a target protein have the general formula: peptide-HBL-antisense in which the peptide is a homing peptide which directs the conjugate to cells of a particular type, antisense is an antisense oligonucleotide having a sequence selected to provide sequence-specific inhibition of the target protein, and HBL is a heterobifunctional linker having reactivity towards amino and sulfhydryl groups.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: November 25, 2014
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Robert Benezra, Erik Henke
  • Publication number: 20140328797
    Abstract: The invention provides isolated fully human monoclonal anti-HRV antibodies, as well as method of making and using these antibodies. Anti-HRV antibodies of the invention prevent or treat subjects having HRV-infections, and related diseases, including, but not limited to, the common cold, nasopharyngitis, croup, pneumonia, bronchiolitis, asthma, chronic obstructive pulmonary disease (COPD), sinusitis, bacterial superinfection, and cystic fibrosis.
    Type: Application
    Filed: April 28, 2014
    Publication date: November 6, 2014
    Inventors: Po-Ying Chan-Hui, III, Kristine Swiderek
  • Publication number: 20140329720
    Abstract: The application describes a biosensor system to measure the presence of single molecules of interest or multiple molecules simultaneously in aqueous solutions without the need for trained personnel or dedicated laboratory space. The system uses a lab-on-a-chip platform to contain and manipulate a biosensor component that, through a series of controlled steps, converts the presence of each of the molecule/s of interest into a unique nucleic acid identifier designated by a specific sequence. The generation of the unique nucleic acid identifier is strictly correlated with the presence of the molecule of interest. The platform contains: multiple, sequential, interconnected chambers; transformer coils that induce magnetic fields; the potential for various electric fields; thermal controls; electronics for measurements; and power control.
    Type: Application
    Filed: May 1, 2014
    Publication date: November 6, 2014
    Applicant: Triune IP LLC
    Inventors: Ross E. TEGGATZ, David William PROVANCE
  • Publication number: 20140323544
    Abstract: Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 44 skipping are described.
    Type: Application
    Filed: March 14, 2014
    Publication date: October 30, 2014
    Applicant: SAREPTA THERAPEUTICS, INC.
    Inventors: Richard K. BESTWICK, Diane Elizabeth FRANK
  • Patent number: 8865188
    Abstract: Provided herein are methods and compositions for controlling assembly of modified viral core proteins, for example, into a viral capsid or a nanocage. In some embodiments, the disclosed modified viral core proteins comprise at least one mutation or modification that can substantially prevent assembly of the viral core proteins until assembly is desired. In some embodiments, assembly of the viral core proteins may be triggered, for example, by contacting the viral core proteins with a reducing agent and/or by reducing the concentration of a denaturant. The viral core proteins may self-assemble to form a viral capsid or nanocage.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: October 21, 2014
    Assignee: Biomed Realty, L.P.
    Inventors: Miguel de los Rios, Stephanie de los Rios, Jacek Ostrowski, Kenneth J. Oh, Ilan Zipkin
  • Publication number: 20140308520
    Abstract: The bio-programmable crystallization of multi-component functional nanoparticle systems is Ascribed, as well as methods for such bio-programmable crystallization, and the products resultant from such methods. Specifically, the systems disclosed and taught herein are directed to improved strategies for the DNA-mediated self-assembly of multi-component functionalized nanoparticles into three-dimensional order surperlattices, wherein the functionalization of the nanoparticles with DNA is independent of either the composition of the material, or the shape of the nanoparticles.
    Type: Application
    Filed: April 12, 2012
    Publication date: October 16, 2014
    Applicant: BROOKHAVEN SCIENCE ASSOCIATES, LLC
    Inventors: Yugang Zhang, Fang Lu, Oleg Gang, Daniel Van Der Lelie
  • Publication number: 20140302510
    Abstract: The present invention relates to a method of diagnosis, prognostic or treatment of neurodegenerative diseases, in particular Alzheimer's disease.
    Type: Application
    Filed: October 15, 2012
    Publication date: October 9, 2014
    Inventors: Dulce Papy-Garcia, Minh Bao Huynh, Nadia Soussi-Yanicostas, Rita Vozari, Fernando Sineriz, Constantin Yanicostas
  • Publication number: 20140296111
    Abstract: A protein-immobilizing solid phase is a protein-immobilizing solid phase comprising an mRNA-nucleic acid linker-protein complex, obtained by linking the mRNA and the protein encoded by that mRNA through the nucleic acid linker, immobilized on the solid phase, wherein the nucleic acid linker has a photocleavage site and a solid phase binding site.
    Type: Application
    Filed: April 30, 2014
    Publication date: October 2, 2014
    Applicants: Nikon Corporation, The University of Tokyo
    Inventors: Shingo Ueno, Naoto Nemoto, Takanori Ichiki, Hirofumi Shiono, Hisao Osawa
  • Patent number: 8815568
    Abstract: The invention provides eukaryotic unicellular algae engineered to express a nucleosome alteration protein fused to a protein with affinity to the DNA binding site acting in coordination. An example is a LexA-p300 fusion protein, where the p300 is derived from Chlamydomonas. The LexA binding domain guides the p300 to the binding site and the p300 loosens the nucleosome structure by acetylating histones within proximity of the transgene, thus remodeling the local chromatin structure to allow for high-level expression.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: August 26, 2014
    Assignee: Synaptic Research, LLC
    Inventors: George Oyler, Julian Rosenberg
  • Publication number: 20140234274
    Abstract: The present invention provides methods of achieving directed evolution of viruses by in vivo screening or “panning” to identify viruses comprising scrambled AAV capsids having characteristics of interest, e.g., tropism profile and/or neutralization profile (e.g., ability to evade neutralizing antibodies). The invention also provides scrambled AAV capsids and virus particles comprising the same.
    Type: Application
    Filed: January 17, 2014
    Publication date: August 21, 2014
    Applicant: University of North Carolina at Chapel Hill
    Inventors: Xiao Xiao, Lin Yang
  • Publication number: 20140235508
    Abstract: A nucleic acid linker is for producing a complex of mRNA and a protein encoded by that mRNA, comprising one 3?-terminal region and two branched 5?-terminal regions, wherein the 3?-terminal region comprises a single-stranded polynucleotide segment able to hybridize with the sequence on the 3?-terminal side of the mRNA, and an arm segment that branches off from the single-stranded polynucleotide segment and has a linking segment with the protein on the terminal thereof, and one of the two 5?-terminal regions has a binding site with the 3?-terminal of the mRNA.
    Type: Application
    Filed: April 30, 2014
    Publication date: August 21, 2014
    Applicants: National University Corporation Saitama University, Nikon Corporation
    Inventors: Naoto Nemoto, Shingo Ueno, Hirofumi Shiono
  • Publication number: 20140234209
    Abstract: The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific CDR sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. More preferably, the antibodies or fragments also comprise specific constant region sequences, such as those associated with the nG1m1,2 or Km3 allotypes. The antibodies or fragments may bind to a human histone protein, such as H2B, H3 or H4. The antibodies or fragments are of use to treat a variety of diseases that may be associated with histones, such as autoimmune disease (e.g.
    Type: Application
    Filed: February 14, 2014
    Publication date: August 21, 2014
    Applicant: Immunomedics, Inc.
    Inventors: Chien-Hsing Chang, Hans J. Hansen, David M. Goldenberg
  • Publication number: 20140221233
    Abstract: The current invention relates to a method for identifying a subject at risk of developing an idiopathic inflammatory myopathy and/or diagnosing a subject suffering from an idiopathic inflammatory myopathy, preferably wherein said idiopathic inflammatory myopathy is Inclusion Body Myositis. The invention provides methods in diagnosis, use of specific antigens, and kits for use in studying the presence or absence of (auto)antibodies in samples derived from subjects.
    Type: Application
    Filed: July 5, 2012
    Publication date: August 7, 2014
    Applicants: STICHTING KATHOLIEKE UNIVERSITEIT, STICHTING KATHOLIEKE UNIVERSITEIT
    Inventors: Gerardus Jozef Maria Pruijn, Wilhelmina Lamberta Leonarda Petronella Pluk, Basilius Gerardus Maria Van Engelen
  • Publication number: 20140206014
    Abstract: The invention relates to a method for detecting and measuring the presence of mono-nucleosomes and oligo-nucleosomes and nucleosomes that contain particular histone variants and the use of such measurements for the detection and diagnosis of disease. The invention also relates to a method of identifying histone variant biomarkers for the detection and diagnosis of disease and to biomarkers identified by said method.
    Type: Application
    Filed: August 31, 2012
    Publication date: July 24, 2014
    Inventor: Jacob Vincent Micallef
  • Publication number: 20140206560
    Abstract: Using a nucleic acid construct, association of a polypeptide with a sequence coding therefor and screening of a polypeptide that binds to a target substance are carried out, which nucleic acid construct comprises a 5?-untranslated region and a coding region, wherein the above-mentioned coding region comprises a sequence coding for a polypeptide subjected to be displayed, a sequence coding for a first nucleic acid binding polypeptide, and a sequence coding for a second nucleic acid binding polypeptide; the above-mentioned 5?-untranslated region comprises a first sequence capable of binding to a first nucleic acid binding polypeptide and a second sequence capable of binding to second nucleic acid binding polypeptide; and, when the above-mentioned nucleic acid construct is introduced in a translation system, a fusion protein translated from the coding region of the above-mentioned nucleic acid construct forms a complex with an RNA corresponding to the above-mentioned nucleic acid construct.
    Type: Application
    Filed: May 23, 2012
    Publication date: July 24, 2014
    Applicant: RIKEN
    Inventors: Akira Wada, Hiroyuki Osada
  • Publication number: 20140196176
    Abstract: The invention provides methods for isolating cell-type specific mRNAs by selectively isolating ribosomes or proteins that bind mRNA in a cell type specific manner, and, thereby, the mRNA hound to the ribosomes or proteins that bind mRNA. Ribosomes, which are riboprotein complexes, bind mRNA that is being actively translated in cells. According to the methods of the invention, cells are engineered to express a molecularly tagged ribosomal protein or protein that binds mRNA by introducing into the cell a nucleic acid comprising a nucleotide sequence encoding a ribosomal protein or protein that binds mRNA fused to a nucleotide sequence encoding a peptide tag. The tagged ribosome or mRNA binding protein can then be isolated, along with the mRNA bound to the tagged ribosome or mRNA binding protein, and the mRNA isolated and further used for gene expression analysis.
    Type: Application
    Filed: June 28, 2013
    Publication date: July 10, 2014
    Inventors: Nathaniel Heintz, Tito A. Serafini, Andrew W. Shyjan
  • Patent number: 8759103
    Abstract: The present invention provides a polynucleotide delivery system including a cationic polymer to which a rabies virus glycoprotein (RVG) peptide is bound, wherein the cationic polymer includes a biodegradable bond, and a method of delivering polynucleotides to a target cell by using the delivery system.
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: June 24, 2014
    Assignee: Postech Academy-Industry Foundation
    Inventors: Won Jong Kim, Do Won Hwang, Dong Soo Lee, Se Jin Son
  • Publication number: 20140120576
    Abstract: The invention relates to a nucleic acid which is stabilised against decomposition by exonucleases. Said nucleic acid contains the following constituents: a) a code sequence coding for a defined protein, b) optionally, a promoter sequence controlling the expression of the code sequence, and c) at least one molecule A added to an end of the linear sequence containing the constituents a and b, said molecule being linked to a non-immobilised, volumic molecule B.
    Type: Application
    Filed: June 20, 2013
    Publication date: May 1, 2014
    Applicant: SIEMENS BUILDING TECHNOLOGIES AG
    Inventors: Helmut Merk, Wolfgang Stiege
  • Publication number: 20140107179
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Application
    Filed: October 1, 2013
    Publication date: April 17, 2014
    Applicant: Novartis AG
    Inventors: Antonin DE FOUGEROLLES, John L. DIENER, Emma HICKMAN, Gregory HINKLE, Stuart MILSTEIN, Anne-Marie PULICHINO, Andrew Griffin SPRAGUE
  • Patent number: 8697410
    Abstract: Improved Sso7-polymerase conjugate proteins are provided.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: April 15, 2014
    Assignee: Bio-Rad Laboratories, Inc.
    Inventor: Man Cheng
  • Publication number: 20140080766
    Abstract: The present invention features compositions and methods for delivering a therapeutic agent to the cytoplasm of a cell. We have developed, inter alia, a system in which two or more distinct moieties—at least one therapeutic moiety and at least one potentiating moiety—selectively target and specifically bind cell surface molecules that are then internalized to an intracellular, membrane-bound compartment, such as an endosome. In some embodiments, as discussed further below, a third moiety that induces clustering of the targeted cell surface molecule can also be employed. Regardless of whether the compositions and methods include two or three moieties, the therapeutic agent can be any agent one wishes to deliver to the cytoplasm of a cell, and the potentiating agent can be any agent that destabilizes the intracellular, sub-cellular compartment in which the therapeutic agent is sequestered. The potentiating moiety can include, for example, a lytic agent (i.e.
    Type: Application
    Filed: January 7, 2012
    Publication date: March 20, 2014
    Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Christopher Michael Pirie, David Victor Liu, Nicole Jie Yeon Yang, Karl Dane Wittrup
  • Publication number: 20140065172
    Abstract: The present invention relates to a delivery system that comprises a conjugate that facilitates the delivery of a compound such as a biologically-active macromolecule, a nucleic acid or a peptide in particular, into a cell. The present invention also relates to said conjugate for delivery of a compound, such as a biologically-active macromolecule, a nucleic acid or a peptide, into a cell. The present invention further relates to a pharmaceutical composition comprising said conjugate and to its use. The present invention also relates to a method of delivering a compound to a cell or an organism, preferably a patient.
    Type: Application
    Filed: January 26, 2012
    Publication date: March 6, 2014
    Inventors: Christophe J. Echeverri, Birte Sönnichsen, Reinhard Wähler, Mike Werner Helms, Brian S. Sproat
  • Publication number: 20140039039
    Abstract: The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.
    Type: Application
    Filed: October 15, 2013
    Publication date: February 6, 2014
    Applicant: NOVARTIS AG
    Inventors: Gregory HINKLE, Satyanarayana KUCHIMANCHI, Stuart MILSTEIN, Markus WARMUTH, Wenlai ZHOU, Ping ZHU, Tracy S. ZIMMERMANN
  • Publication number: 20140037554
    Abstract: The present invention discloses methods and materials for delivering a cargo compound into a cancer cell. Delivery of the cargo compound is accomplished by the use of protein transduction domains derived from cupredoxins. The invention further discloses methods for treating cancer and diagnosing cancer.
    Type: Application
    Filed: September 9, 2013
    Publication date: February 6, 2014
    Applicant: The Boad of Trustees of the University of Illinois
    Inventors: Ananda Chakrabarty, Tapas Das Gupta, Tohru Yamada, Arsenio Fialho
  • Publication number: 20140030787
    Abstract: Provided is a composition comprising an analyte bound covalently or through a first binding pair to a polymer. In this composition, the analyte is less than about 2000 MW; the polymer further comprises more than one signal or first member of a second binding pair; and the analyte is not a member of the first binding pair or the second binding pair. Also provided is an assay for an analyte. The assay comprises: combining a sample suspected of containing the analyte with the above-described composition and a binding agent that binds to the analyte; and detecting the signal or the first member of the second binding pair that is bound to the binding agent. In this assay, the amount of the signal or the first member of the second binding pair bound to the binding agent is inversely proportional to the analyte in the sample.
    Type: Application
    Filed: July 24, 2012
    Publication date: January 30, 2014
    Inventors: JACK COLEMAN, MACIEJ SZCZEPANIK, RICHARD JIN
  • Publication number: 20140011700
    Abstract: The binding mode of the antiviral compounds have been characterized through a variety of biophysical and structural studies, elaborating on the proposed aggregation mechanism of action. We demonstrate the direct binding of these antiviral compounds to NP using thermal shift enhancement assay (TSE) and NMR. In addition, we have completed a detailed analysis of the oligomerization mechanism of action using dynamic light scattering, analytical ultracentrifugation, and surface plasmon resonance (SPR). Structure determination using x-ray crystallography confirmed the proposed compound-induced oligomerization mechanism of action. The co-crystal structure revealed that two compounds bound in an anti-parallel fashion bridging two NP monomers, inducing a novel non-native NP oligomer.
    Type: Application
    Filed: March 23, 2012
    Publication date: January 9, 2014
    Inventors: Eric T. Baldwin, Patricia Ann McDonnell, Suzanne Edavettal, Hal Lewis, Bradley C. Pearce, David R. Langley, Christopher W. Cianci, Linda Discotto, Samuel Gerritz, Shuhao Shi, Shirong Zhu
  • Publication number: 20130344564
    Abstract: The invention relates to compositions of vault complexes containing recombinant membrane lytic proteins, such as an adenovirus protein VI lytic domain, and methods of using the vault complexes to facilitate delivery and entry of a biomolecule into a cell or subject.
    Type: Application
    Filed: September 4, 2013
    Publication date: December 26, 2013
    Applicants: The Scripps Research Institute, The Regents of the University of California
    Inventors: Leonard H. Rome, Valerie A. Kickhoefer, Glen R. Nemerow, Cheng-Yu Lai, Chris M. Weithoff, Mu Ri Han
  • Publication number: 20130344094
    Abstract: Herein is reported a polypeptide-polynucleotide-complex as therapeutic agent and its use as tool for the targeted delivery of an effector moiety. The polynucleotide part of the complex is essentially resistant to proteolytic and enzymatic degradation in vivo. Additionally the polypeptide part specifically binds to a compound or structure such as a tissue or organ, a process or a disease. Thus, one aspect as reported herein is a polypeptide-polynucleotide-complex comprising a) a polypeptide specifically binding to a target and conjugated to a first member of a binding pair, b) a polynucleotide linker conjugated at its first terminus to the second member of the binding pair, and c) an effector moiety conjugated to a polynucleotide that is complementary to at least a part of the polynucleotide linker.
    Type: Application
    Filed: June 21, 2013
    Publication date: December 26, 2013
    Inventors: Michael Gerg, Dieter Heindl, Gerhard Niederfellner, Wolfgang Schaefer, Michael Schraeml, Michael Tacke
  • Publication number: 20130330826
    Abstract: The present invention provides a polynucleotide delivery system including a cationic polymer to which a rabies virus glycoprotein (RVG)peptide is bound, wherein the cationic polymer includes a biodegradable bond, and a method of delivering polynucleotides to a target cell by using the delivery system.
    Type: Application
    Filed: August 25, 2011
    Publication date: December 12, 2013
    Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATION
    Inventors: Won Jong Kim, Do Won Hwang, Dong Soo Lee, Se Jin Son
  • Publication number: 20130316912
    Abstract: Compositions and methods are provided for nucleotide analogs comprising protein shields for improving enzyme photostability in single molecule real time sequencing. Nucleotide analogs of the invention have a protein shield between the dye moieties and nucleotide moieties of the analog. The protein prevents the direct interaction of the dye moiety with the enzyme carrying out nucleotide synthesis preventing photodamage to the enzyme. The nucleotide analogs of the invention can have multiple dyes and multiple nucleotide moieties.
    Type: Application
    Filed: February 14, 2013
    Publication date: November 28, 2013
    Applicant: Pacific Biosciences of California, Inc.
    Inventors: Keith Bjornson, Jeremiah Hanes, Erik Miller, Satwik Kamtekar, Lubomir Sebo, Louis Brogley
  • Publication number: 20130288364
    Abstract: The invention provides modified DNA-binding kinetochore polypeptides, wherein the modified DNA binding kinetochore polypeptides comprise a heterologous DNA binding domain. The invention further provides engineered kinetochores containing the modified kinetochore polypeptides. Further provided are artificial chromosomes containing an engineered kinetochore. Cells containing an artificial chromosome containing an engineered kinetochore are also provided. Methods for producing and methods of using the engineered kinetochore, artificial chromosome, and cells are also provided.
    Type: Application
    Filed: October 28, 2011
    Publication date: October 31, 2013
    Applicant: Whitehead Institute for Biomedical Research
    Inventors: Iain Cheeseman, Karen Gascoigne